Objective. To compare the efficiency of transcutaneous electrical acupoint stimulation (TEAS) with those of conventional and TCM herb on bone marrow suppression in small cell lung cancer (SCLC) patients after initial chemotherapy. Methods. We recruited 139 participants with pathologically confirmed SCLC who had not received chemotherapy. The conventional group (nβ=β37) received gemcitabine and cisplatin chemotherapy and routine care. The TCM herb group (nβ=β35) received 3 Diyushengbai tablets thrice a day for one day prior to chemotherapy and maintained during the trial. The TEAS group (nβ=β42) received TEAS at a frequency of 65β100βHz with a pulse width of 100β200 ΞΌsec. Acupoints were selected from Dazhui (DU14), Geshu (BL17), Zusanli (ST36), Sanyinjiao (SP6), and Hegu (LI4) and were treated on days 1, 2, 3, 5, 8, 14, 21, and 28 of chemotherapy for 30βmin each day. All three groups underwent a 28-day treatment for a total of one treatment course. Changes in the white blood cell, neutrophil, platelet, and hemoglobin indices on day 1 before chemotherapy and days 5, 8, 11, 14, 21, and 28 days after chemotherapy were compared among the groups. Comfort levels of patients on day 1 before chemotherapy and days 5, 11, and 21 after chemotherapy were observed. Results. Compared with the conventional group, the white blood cell counts in the TEAS group on days 8 (7.07βΒ±β2.11 vs. 5.97βΒ±β2.10βΓβ109/L) and 14 (6.14βΒ±β1.51 vs. 5.07βΒ±β2.41βΓβ109/L) of chemotherapy and that in the TCM herb group on day 14 (6.63βΒ±β3.44 vs. 5.07βΒ±β2.41βΓβ109/L) of chemotherapy were increased (
P
<
0.05
). Compared with the conventional group, the neutrophil count in the TEAS group on days 5 (4.28βΒ±β1.54 vs. 3.01βΒ±β1.41βΓβ109/L), 8 (3.75βΒ±β1.21 vs. 2.77βΒ±β1.17βΓβ109/L), 11 (3.46βΒ±β1.31 vs. 2.31βΒ±β1.24βΓβ109/L), 14 (3.18βΒ±β1.29 vs. 2.07βΒ±β1.14βΓβ109/L), and 21 (4.67βΒ±β1.31 vs. 3.58βΒ±β1.23βΓβ109/L) of chemotherapy and that in the TCM herb group on day 5 (3.88βΒ±β1.05 vs. 3.01βΒ±β1.41βΓβ109/L) of chemotherapy were increased (
P
<
0.05
). Compared with the conventional group, the platelet count of patients in the TEAS group increased on days 5 (264.7βΒ±β64.1 vs. 201.0βΒ±β55.7βΓβ109/L), 8 (251.3βΒ±β74.9 vs. 188.2βΒ±β65.8βΓβ109/L), 11 (236.7βΒ±β74.9 vs. 181.3βΒ±β84.3βΓβ109/L), and 14 (238.3βΒ±β75.9 vs. 192.8βΒ±β95.8βΓβ109/L) of chemotherapy (
P
<
0.05
). Compared with the TCM herb group, the platelet count in the TEAS group increased on days 5 (264.7βΒ±β64.1 vs. 216.3βΒ±β57.9βΓβ109/L), 8 (251.3βΒ±β74.9 vs. 213.7βΒ±β70.3βΓβ109/L), 11 (236.7βΒ±β74.9 vs. 181.3βΒ±β84.3βΓβ109/L), and 21 (254.8βΒ±β81.8 vs. 213.9βΒ±β82.6βΓβ109/L) of chemotherapy (
P
<
0.05
). Compared with the conventional group, the hemoglobin level in the TCM herb group increased on day 14 (135.03βΒ±β28.06 vs. 122.09βΒ±β12.63βg/L) of chemotherapy (
P
<
0.05
). Compared with the conventional group, the comfort score of the TEAS group increased on days 5 (78.31βΒ±β10.21 vs. 70.18βΒ±β9.34 score) and 11 (80.07βΒ±β10.44 vs. 72.11βΒ±β9.47 score) of chemotherapy (
P
<
0.05
). Conclusion. TEAS is an effective and safe treatment modality for improving bone marrow suppression in SCLC patients after initial chemotherapy. TEAS improved comfort levels more effectively than did conventional and TCM herb.